Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

Clin Infect Dis. 2006 Jul 15;43(2):253-5. doi: 10.1086/505210. Epub 2006 Jun 12.

Abstract

Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / blood*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / methods
  • Antitubercular Agents / therapeutic use*
  • Drug Interactions
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Nevirapine / blood*
  • Nevirapine / therapeutic use
  • Prospective Studies
  • Rifampin / therapeutic use*
  • Treatment Outcome
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*

Substances

  • Anti-HIV Agents
  • Antitubercular Agents
  • Nevirapine
  • Rifampin